Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Prana – ANA Abstract Submission NLP

October 17, 2016 Kerry Rowe

final-ana-abstract-submission-nlp-4-8-16

Post navigation

New data from Reach2HD trial presented at American Neurological Association Annual Meeting

Related Posts

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

June 30, 2020May 19, 2021

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019May 27, 2019

Prana AGM Webcast Details

November 10, 2015

Recent Posts

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Presentation of New Biomarker Data at Scientific Congress
XBRL 30 June 2021 filed with the SEC
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065